Search alternatives:
patients decrease » point decrease (Expand Search), treatments decreased (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
peer decrease » teer decrease (Expand Search), mean decrease (Expand Search), step decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
Showing 1 - 20 results of 10,349 for search '(( b large decrease ) OR ((( via ((peer decrease) OR (_ decrease)) ) OR ( _ patients decrease ))))', query time: 0.50s Refine Results
  1. 1
    Naringenin decreases total cell viability.

    Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Loss of Vps34 is associated with decreased eTreg survival but intact activation.

    Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms.

    Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms. by Janaína de Pina Carvalho (12152812)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    <b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"

    <b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

    Published 2025
    Save to List
    Saved in:
  6. 6
    Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression

    Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

    Published 2025
    “…</p> <p>To investigate this, we analyzed the expression of interferon-stimulated genes (ISGs) in 48 SARS-CoV-2-infected patients using real-time polymerase chain reaction (RT-qPCR) and assessed toll-like receptor (TLR7) expression in blood cells via flow cytometry.…”
    Save to List
    Saved in:
  7. 7
    Patient demographics.

    Patient demographics. by Tuğba Kocahan (21246715)

    Published 2025
    Subjects: “…disability subscores decreased…”
    Save to List
    Saved in:
  8. 8
    Patient characteristics and procedural data.

    Patient characteristics and procedural data. by Jonathan Nadjiri (665209)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 9
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Overview of study procedures.

    Overview of study procedures. by Matthew G. Vinson (22593374)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis

    Supplementary Material for: Decreased Quality of Life in patients who desire Body Contouring Surgery after Bariatric Metabolic Surgery: A multicenter longitudinal analysis by Dijkhorst P.J. (20584910)

    Published 2025
    Save to List
    Saved in:
  12. 12
    Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class.

    Percentage of positive responses to overall satisfaction 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class.

    Percentage of positive responses to access question 2011/12 by A) Age and sex B) SIMD decile C) Number of Health Issues and D) Urban/Rural Class. by David Henderson (4612354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: